Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Targovax ASA ( (GB:0RIS) ) has shared an update.
Circio Holding ASA has announced its annual general meeting scheduled for June 5, 2025, at its Oslo offices. The company is advancing its RNA technology and cancer vaccine projects, with significant progress in clinical trials and research collaborations, supported by grants from Innovation Norway and the Norwegian Research Council.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, known as circVec, which enhances protein expression significantly compared to traditional mRNA systems. This platform is applicable in various therapeutic areas, including genetic medicine and chronic disease. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,153,905
Current Market Cap: NOK62.66M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.